LXXXVI . POLYSACCHARIDES SYNTHESISED BY MICRO-ORGANISMS III . THE MOLECULAR STRUCTURE OF GALACTO-CAROLOSE PRODUCED FROM GLUCOSE BY PENICILLIUM CHARLESII

G. Smith,W. Haworth,H. Raistrick,'. Mauricestacey

Abstract:

What problem does this paper attempt to address?

Lichen planus flare following COVID‐19 vaccination: A case report

Astrid Herzum,Martina Burlando,Mattia F. Molle,Claudia Micalizzi,Emanuele Cozzani,Aurora Parodi

DOI: https://doi.org/10.1002/ccr3.5092

2021-12-01

Clinical Case Reports

Abstract:We report the third case of cutaneous lichen planus (LP) following COVID-19 BNT162b2 vaccination in a 59-year-old woman with previous LP. The reactivation of LP in patients with dormant LP suggests a possible vaccine-induced immune dysregulation. We suggest that the already described vaccine-induced upregulation of Th1 response may play a relevant role in LP reactivation, through an increase in inflammatory cytokines involved in the pathogenesis of LP. Interestingly, LP has already been associated with vaccinations and viral infections including COVID-19 disease. However, the exact mechanism underlying LP (re)activation after Pfizer-BiotNtech COVID-19 vaccination is still widely unknown and needs to be further investigated.
COVID-19-Vaccination-Induced Localized Lichen Planus Successfully Treated With Phototherapy

Mahdi Al Dhafiri

DOI: https://doi.org/10.7759/cureus.66907

2024-08-14

Cureus

Abstract:Lichen planus (LP) is an inflammatory autoimmune mucocutaneous disease with different forms and presentations. It mainly affects the skin and oral mucosa but could also affect genital mucosa, nails, hair, and, rarely, the larynx and esophagus. Since the start of the COVID-19 era, multiple cutaneous manifestations related to SARS-CoV-2 infection or vaccination have been reported. Different rare cases of lichen planus were reported after COVID-19 infection and vaccination. This report elaborates on and adds an additional case of localized cutaneous lichen planus (CLP) to the upper extremities, which developed after both doses of the mRNA vaccine and improved after phototherapy.
Chronic oral diseases secondary to COVID-19 infection or vaccination: clinical cases and a narrative review

Sarah Fitzpatrick,Seunghee Cha,Joseph Katz,Cesar Migliorati

DOI: https://doi.org/10.3290/j.qi.b5031811

2024-05-30

Abstract:Objectives: Autoimmune activation by COVID-19 infection/vaccination has been postulated to be responsible for initiating or reactivating multiple types of oral mucosal immune disorders. These include: oral lichen planus; oral pemphigoid; either bullous pemphigoid or mucous membrane pemphigoid with oral involvement; pemphigus vulgaris with oral involvement; and Sjögren disease. In addition, chronic conditions such as oral burning, xerostomia, or changes in taste and/or smell have also been linked to COVID-19 infection/vaccination. Data sources: Part 1 (mucosal conditions): an English-language literature review of Pubmed, Web of Science, Scopus, and Embase was performed searching cases of oral lichen planus, oral bullous pemphigoid, mucous membrane pemphigoid, pemphigus vulgaris, and COVID-19 infection/vaccination, with additional cases from the authors' clinical practice presented. Part 2 (nonmucosal conditions): Cases of initiated or flared Sjögren disease, chronic oral burning, or xerostomia after COVID-19 infection/vaccination from the authors' clinical practice were aggregated. Results: The literature review discovered 29 cases of oral lichen planus following COVID-19 infection/vaccination. For bullous pemphigoid, 10 cases were identified after infection/vaccination. The number of pemphigus vulgaris cases following infection/vaccination was 28. The majority of mucosal cases were reported after vaccination. Most reported initial disease, but a substantial amount included recurrences of existing diseases. Nonmucosal disease: Sjögren disease, chronic oral burning, or xerostomia after COVID-19 infection/vaccination cases totaled 12 cases identified from the authors' clinical practice, with the majority occurring after infection. Conclusions: Chronic conditions after infection with COVID-19 or vaccination remain relatively rare and self-limited, yet reinforce the importance of comprehensive history taking involving COVID-19 to differentiate potential etiologic factors for these conditions.
Oral lesions after COVID-19 vaccination: Immune mechanisms and clinical approach

Mohammad Amin Khazeei Tabari,Shaghayegh Najary,Gita Khadivi,Mohammad Javad Yousefi,Noosha Samieefar,Fahimeh Abdollahimajd

DOI: https://doi.org/10.1016/j.imj.2022.06.004

Abstract:COVID-19 vaccination, although is a promising tool to overcome the pandemic, has side effects. There are increasing reports of oral lesions after COVID-19 vaccination. The aim of this review is to identify the occurrence of some oral lesions after COVID-19 vaccination, and highlight the underlying immune mechanisms involved. A narrative literature review was performed by searching electronic databases including PubMed, Scopus and Web of Science to investigate the oral lesions after COVID-19 vaccination. The inclusion criteria were original studies, including the case reports, case series, letter to the editor, and cross-sectional studies. The exclusion criteria included the studies which examined the oral lesions caused by COVID-19 infection. The information, including the number of participant(s) receiving vaccine, type of vaccine, dose number, side effect(s), time of onset following vaccination, healing time, treatment strategies for the existing lesions, and related mechanisms were then summarized in a data extraction sheet. The results of this review showed that some vaccines had side effects with oral involvement such as pemphigus vulgaris, bullous pemphigoid, herpes zoster, lichen planus, Stevens-Johnson syndrome and Behçet's disease. Future research needs to elucidate the physiopathology of oral manifestations after the COVID-19 vaccination, and better understand the risk factors associated with such responses. Sometimes vaccine's side effects may be due to the nocebo effect, which means that the person expects some adverse events to occur following the vaccine administration.
Onset of leukocytoclastic vasculitis following covid-19 vaccination: case based comprehensive review

Rada Miskovic,Sara Radovic,Snezana Arandjelovic,Aleksandra Plavsic,Vesna Reljic,Jelena Peric,Voin Brkovic,Maja Stojanovic

DOI: https://doi.org/10.1007/s00296-024-05718-x

2024-09-26

Rheumatology International

Abstract:With the global introduction and widespread administration of COVID-19 vaccines, there have been emerging reports of associated vasculitis, including leukocytoclastic cutaneous vasculitis (LCV). In this paper, we present a case of a 68-year-old female patient who developed painful purpuric skin lesions on her feet 12 days after administration of the inactivated COVID-19 vaccine BBIBP Cor-V with histopathological confirmation of LCV and no signs of systemic involvement. The case is followed by a comprehensive literature review of documented LCV cases associated with COVID-19 vaccination with overall 39 articles and 48 cases of LCV found in total. In the majority of cases (56.3%) the first symptom occurred after the first dose of the COVID-19 vaccine, with symptoms manifesting within an average of seven days (6.8 ± 4.8) post-vaccination. The adenoviral vaccine Oxford-AstraZeneca (41.7%) and the mRNA vaccine Pfizer-BioNTech (27.1%) were most frequently associated with LCV occurrences. On average, LCV resolved within 2.5 (± 1.5) weeks. The preferred treatment modality were glucocorticoids, used in 70.8% of cases, resulting in a positive outcome in most cases, including our patient. While the safety of a subsequent dose appears favorable based on our review, individual risk–benefit assessment is crucial. This review emphasis the importance of considering COVID-19 vaccination as a potential trigger for the development of cutaneous vasculitis. Despite rare adverse events, the benefits of the COVID-19 vaccination outweigh the risks, highlighting the importance of immunization programs.

rheumatology
Clinicopathological characteristics of cutaneous complications following COVID-19 vaccination: A case series

Reem Diab,Azadeh Rakhshan,Sareh Salarinejad,Mohammad Reza Pourani,Padideh Ansar,Fahimeh Abdollahimajd

DOI: https://doi.org/10.1111/jocd.16042

Abstract:Introduction: Several vaccine-related cutaneous adverse events occurred following the widespread use of vaccines to prevent coronavirus disease 2019 (COVID-19). This case series reports 25 patients with de novo or accentuated dermatologic conditions after receiving the Sinopharm, Sputnik V, AstraZeneca, or BIV1-CovIran vaccine in Iran. Methods and results: Twenty-five eligible patients with a mean age of 46.80 years were investigated. The cutaneous adverse events included pityriasis rosea, zoster, viral exanthema, urticaria, bullous pemphigoid, pemphigus vulgaris, and acute generalized exanthematous pustulosis. The manifestations appeared 14.45 ± 6.98 and 20.79 ± 22.18 days following injection of the first and second doses of COVID-19 vaccines, respectively. All patients experienced new cases of cutaneous disease other than two who developed flare-ups of lichen planus and psoriasis. Conclusion: Several cutaneous reactions, ranging from allergic events to skin diseases, have been reported following the injection of COVID-19 vaccines. Focal injection-site reactions are the most common cutaneous adverse events; however, de-novo skin diseases and a flare-up of preexisting cutaneous disorders have also been described. Although many cases of COVID-19 vaccine-related cutaneous diseases have been published, our zoster/lichen planus and AGEP cases after vaccination are interesting. A more detailed understanding of cutaneous adverse events following COVID-19 vaccination will facilitate better diagnosis and management.
Viral Reactivation Following COVID-19 Vaccination: a review of the current literature

Fabrizio Martora,Matteo Megna,Teresa Battista,Massimiliano Scalvenzi,Alessia Villani,Sara Cacciapuoti,Luca Potestio

DOI: https://doi.org/10.1093/ced/llae061

2024-02-20

Clinical and Experimental Dermatology

Abstract:Abstract Background Currently, four vaccines for COVID-19 have been licensed by the European Medi-cines Agency: viral vector-based vaccines (AstraZeneca; AZD1222 and Johnson & Johnson; Ad26.COV2. and 2 mRNA-based vaccines (Pfizer/BioNTech; BNT162b2 and Moderna; mRNA-1273). Since their approval, several cutaneous reactions related to vaccination have been reported in the literature. Among these, viral reactivations are one of the most frequent. Objectives The aim of this manuscript was to investigate current literature regarding viral reactivations following COVID-19 vaccination, focusing the attention on Pityriasis Rosea, Herpes Zoster and Herpes Simplex. Methods A comprehensive literature research using various databases, including metanalyses, re-views, letters to the editor, real-life studies, case series, and reports, was performed. Results A total of 47 articles involving about 2000 patients were selected. Of these, 32, 6 and 17 articles reported VZV reactivation (1,758 cases), HSV (238 cases) onset and PR (71 cases), respectively. Conculsion Possible pathogenetic mechanisms underlying viral reactivation are not still understood as well as the possible correlations between vaccination and viral reactivation should be clarified. Certainly, vaccination should not be discouraged.

dermatology
Cutaneous findings following COVID‐19 vaccination: review of world literature and own experience

T. Gambichler,S. Boms,L. Susok,H. Dickel,C. Finis,N. Abu Rached,M. Barras,M. Stücker,D. Kasakovski

DOI: https://doi.org/10.1111/jdv.17744

2021-11-02

Journal of the European Academy of Dermatology and Venereology

Abstract:There is growing evidence that not only the novel coronavirus disease (COVID-19) but also the COVID-19 vaccines can cause a variety of skin reactions. In this review article, we provide a brief overview on cutaneous findings that have been observed since the emerging mass COVID-19 vaccination campaigns all over the world. Unspecific injection site reactions very early occurring after the vaccination are most frequent. Type I hypersensitivity reactions (e.g., urticaria, angioedema, anaphylaxis) likely due to allergy to ingredients may rarely occur but can be severe. Type IV hypersensitivity reactions may be observed, including delayed large local skin lesions ("COVID arm"), inflammatory reactions in dermal filler or previous radiation sites or even old BCG scars, and more commonly moribilliform and erythema multiforme-like rashes. Autoimmune-mediated skin findings after COVID-19 vaccination include leukocytoclastic vasculitis, lupus erythematosus, and immune thrombocytopenia. Functional angiopathies (chilblain-like lesions, erythromelalgia) may also be observed. Pityriasis rosea-like rashes and reactivation of herpes zoster have also been reported after COVID-19 vaccination. In conclusion, there are numerous cutaneous reaction patterns that may occur following COVID-19 vaccination, whereby many of these skin findings are of immunological/autoimmunological nature. Importantly, molecular mimicry exists between SARS-CoV-2 (e.g., the spike-protein sequences used to design the vaccines) and human components and may thus explain some COVID-19 pathologies as well adverse skin reactions to COVID-19 vaccinations.

dermatology
COVID vaccine–induced lupus nephritis: Case report and review of the literature

Antonio Salas,Ayotola Fatola,Rebecca Krimins,Ihab R Kamel,Duvuru Geetha,Derek Fine,Manny Monroy-Trujillo,Avi Rosenberg,Lois Arend,Homa Timlin

DOI: https://doi.org/10.1177/09612033231222390

IF: 2.858

2024-01-03

Lupus

Abstract:Lupus, Ahead of Print. Vaccines offer an effective strategy to prevent infectious diseases with minimal adverse effects. On rare occasions, vaccination can disrupt the immune response leading to induction of autoimmune diseases. We describe a case of new-onset lupus nephritis following COVID-19 vaccination with the first dose of the Pfizer vaccine. Her symptoms and lab values improved with steroids, hydroxychloroquine, and mycophenolate mofetil.

rheumatology
Primary Cutaneous CD4 Small/Medium T-Cell Lymphoproliferative Disorder Following COVID-19 Vaccination—What Do We Know about Lymphoproliferative Disorders and Cutaneous Lymphomas after COVID-19 Vaccination? A Report of an Atypical Case and a Review of the Literature

Francisco Javier De la Torre-Gomar,Jose María Llamas-Molina,Maria Dolores Pegalajar-García,Carmen Pérez-Valencia,Alejandro Carrero-Castaño,Ricardo Ruiz-Villaverde

DOI: https://doi.org/10.3390/life14030386

2024-03-15

Life

Abstract:The association between Primary cutaneous CD4 small/medium T-cell lymphoproliferative disorder (PCSM-TCLPD) and COVID-19 immunization has been sparsely documented in the medical literature. Reviewing the literature, albeit infrequently, we can find cases of the recurrence and new onset of lymphoproliferative processes and cutaneous lymphomas following the COVID-19 vaccine. Many of the entities we encounter are classified as cutaneous lymphoproliferative disorders. The prevailing hypothesis suggests that the predominant cutaneous reactions to SARS-CoV-2 vaccines may stem from T-cell-mediated immune activation responses to vaccine components, notably messenger RNA (mRNA). Specifically, it is posited that the presence of cutaneous lymphoid infiltrates may be linked to immune system stimulation, supported by the absence, to date, of instances of primary cutaneous B-cell lymphoma following mRNA vaccination. Within this context, it is imperative to underscore that the etiological association between PCSM-TCLPD and COVID-19 vaccination should not discourage vaccination efforts. Instead, it underscores the necessity for continuous surveillance, in-depth investigation, and comprehensive follow-up studies to delineate the specific attributes and underlying mechanisms of such cutaneous manifestations post vaccination.

biology
[Features of colorectal cancer with fecal-occult-blood tests--comparison with colorectal cancer with no screening].

I. Takemasa,N. Kikkawa,M. Yasui,I. Nishisho,K. Fujitani,H. Mishima,Y. Hasuike,K. Kobayashi

1998-08-01

Abstract:BACKGROUND There is now evidence from three randomized controlled trials (from Minnesota, Nottingham and Funen) that screening average-risk individuals for colorectal cancer (CRC) with fecal-occult-blood tests (FOBT) can reduce mortality from CRC. In Japan, mortality rates from CRC have increased and mass screening with FOBT has been performed since 1992. Although there is growing proportion of CRC with FOBT, there is no conclusive evidence that they reduce mortality from this cause. We evaluated the feature of CRC with FOBT, as one of the methods for evaluation of the efficacy of screening with this test. METHODS Between January, 1982 and December, 1996, 2071 cases with CRC resected in our hospital were considered. We evaluated the clinicopathological findings about age, sex, location of tumor, size depth, incidence of lymph node metastasis, stage and prognosis of CRC with FOBT (376) compared with CRC with no screening (controls; 1695). RESULTS CRC with FOBT were earlier stage and smaller-sized cancers than controls. No significant difference was found in the incidence of lymph node metastasis at each depth and prognosis in each stage. CONCLUSIONS By screening with FOBT, we can detect at an earlier stage and with a smaller cancer, with the same biological behavior as controls. Now, we must encourage colon screening, continuing to research ways to improve identification of high-risk subgroups and increase complicance.
COVID-19 and COVID-19 Vaccine-Related Skin Ulcerations in the Lower Extremities: A Case Report and Literature Review

Paul Beaineh,Ayman El-Bsat,Bassel Hafez,Abdul Rahman Bizri,Abdul-Ghani Kibbi,Mira Merashli,Fady Haddad

DOI: https://doi.org/10.1177/15347346241275785

2024-10-30

The International Journal of Lower Extremity Wounds

Abstract:The International Journal of Lower Extremity Wounds, Ahead of Print. Several associations have been made between COVID-19 and vasculitis. Recent data also shows the prevalence and association of de novo vasculitis with either COVID-19 infection or COVID-19 post vaccination. In this article, we present the case of new-onset leukocytoclastic vasculitis, secondary to COVID-19 vaccination, that was complicated by severe infected and nonhealing ulcers in the lower extremities.CaseA 53-year-old male patient presented to the dermatology clinics with a three-week history of painful necrotic patches coalescent of the lateral malleolus of the right and left ankles. History goes back to when the patient reported developing pruritic papules two weeks after receiving his second shot of the Pfizer BioNTech COVID-19 vaccine (BNT162b2). Punch biopsy was consistent with leukocytoclastic vasculitis. He was prescribed a four-week course of systemic corticosteroids and antibiotics as per cultures. Vascular assessment confirmed normal peripheral arterial and venous system. Two months later, the patient re-presented with fever and worsening of his lower extremity ulcers. He underwent debridement of his wounds. Intra-operative cultures revealed multidrug resistant bacteria. He required an additional debridement session a few days later and a 14-day course of Piperacillin-Tazobactam. The patient was subsequently discharged on corticosteroids and Azathioprine and followed up in the vascular surgery and rheumatology clinics. At four months follow-up, the patient's wounds were almost completely healed.ConclusionThis article highlights a case of severe new-onset COVID-19 vaccine-associated leukocytoclastic vasculitis complicated with infected ulcers that required debridement twice in addition to a prolonged course of antibiotics and immunosuppression therapy. To our knowledge, none of the cases reported in the literature were this severe in nature. In this post-pandemic era, it must remain high on the differential list, and healthcare specialists should maintain a high index of suspicion when evaluating sudden new-onset skin lesions that do not have an immediately apparent etiology.

dermatology,surgery
A peculiar post-vaccination eruption

Martina Volonté,Emanuele M Favale,Nicolò Di Giuli,Valeria Brazzelli,Stefania Barruscotti,Giacomo Fiandrino,Carlo F Tomasini,Camilla Vassallo

DOI: https://doi.org/10.1093/ced/llae315

2024-08-13

Clinical and Experimental Dermatology

Abstract:We report the case of a 47-year-old woman who presented the appearance of oral mucositis and vegetative lesions localized at the major skin folds appeared after Comirnaty (BNT162b2) BioNTech anti-SARS-CoV-2 vaccination. Clinical, histological and immunopathological findings led to a diagnosis of pemphigus vegetans (Neumann variant) and the Naranjo score suggested a probable correlation with the vaccination.To our knowledge, despite its rarity, another case of pemphigus vegetans after Comirnaty (BNT162b2) BioNTech anti-SARS-CoV-2 vaccination has already been described in literature.

dermatology
Lipschütz ulcer following first dose of COVID‐19 tozinameran vaccine: Report of a case and review of a World Health Organization pharmacovigilance database

Elliot Ewig,Nouha Ben Othman,Delphine Viard,Pierre‐Alexis Gauci,Fanny Rocher,Milou‐Daniel Drici

DOI: https://doi.org/10.1002/ijgo.15941

2024-10-24

International Journal of Gynecology & Obstetrics

Abstract:Lipschütz ulcer (LU) is a condition known for painful vulvar ulcers, typically affecting young women and often linked to infectious agents. Recent reports have indicated a potential connection between LU and COVID‐19 vaccination, particularly after the second or booster doses. This study presents a case of LU following the first dose of tozinameran in a young woman who had a previous SARS‐CoV‐2 infection and investigates similar cases globally. An 18‐year‐old woman experienced vulvar pain and ulcers 2‐days after her initial COVID‐19 vaccine dose. After ruling out infections through serological tests, a diagnosis of LU was made, and her symptoms resolved after 10 days. A literature search and VigiBase® analysis revealed 11 cases of LU following COVID‐19 vaccination, and 519 vulvovaginal ulcer cases associated with these vaccines were identified in Vigibase®, with a median onset of 2 days. Most LU cases occurred after the second dose or booster shots. The primary hypothesis for this association is a type 3 hypersensitivity reaction mediated by immune complexes, possibly triggered by prior exposure, as many cases occurred after the second dose. Interestingly, the presented case suggests that prior COVID‐19 infection could serve as sensitization. In conclusion, this study highlights the potential occurrence of LU after the initial COVID‐19 vaccine dose in young patients with prior COVID‐19 infection. While the risk of recurrence after subsequent vaccinations or infections remains uncertain, the benefits of vaccination outweigh the risks. Clinicians and patients should be aware of this potential issue to make informed decisions regarding vaccination.

obstetrics & gynecology
Rare COVID-19 vaccine side effects got lost in the shuffle. Primary cutaneous lymphomas following COVID-19 vaccination: a systematic review

Berenika Olszewska,Anna Zaryczańska,Roman J. Nowicki,Małgorzata Sokołowska-Wojdyło

DOI: https://doi.org/10.3389/fmed.2024.1325478

IF: 3.9

2024-04-10

Frontiers in Medicine

Abstract:Introduction COVID-19 vaccines are generally safe and effective; however, they are associated with various vaccine-induced cutaneous side effects. Several reported cases of primary cutaneous lymphomas (CLs) following the COVID-19 vaccination have raised concerns about a possible association. This systematic review aims to investigate and elucidate the potential link between CLs and SARS-CoV-2 vaccines. Methods We performed a systematic literature search on PubMed, EBSCO and Scopus from January 01, 2019, to March 01, 2023, and analyzed studies based on determined eligibility criteria. The systematic review was performed based on the PRISMA protocol. Results A total of 12 articles (encompassing 24 patients) were included in this analysis. The majority of CLs were indolent cutaneous T-cell lymphomas (CTCLs) (66,7%; 16/24), with Lymphomatoid papulosis (LyP) being the most common type (33,3%; 8/24). Most patients (79,2%; 19/24) developed lesions after receiving the COVID-19 mRNA-based vaccines, and predominantly after the first immunization dose (54,2%; 13/24). The presented CLs cases exhibited a tendency to exacerbate following subsequent COVID-19 vaccinations. Nevertheless, CLs were characterized by a favorable course, leading to remission in most cases. Conclusion The available literature suggests an association between the occurrence and exacerbation of CLs with immune stimulation following COVID-19 vaccination. We hypothesize that post-vaccine CLs result from an interplay between cytokines and disrupted signaling pathways triggered by vaccine components, concurrently playing a pivotal role in the pathomechanism of CLs. However, establishing a definitive causal relationship between these events is currently challenging, primarily due to the relatively low rate of reported post-vaccine CLs. Nonetheless, these cases should not be disregarded, and patients with a history of lymphoproliferative disorders require post-COVID-19 vaccination monitoring to control the disease’s course. Systematic review registration www.researchregistry.com , identifier [1723].

medicine, general & internal
Two cases of challenging cutaneous lymphoid infiltrates presenting in the context of COVID‐19 vaccination: a reactive lymphomatoid papulosis‐like eruption and a bona fide lymphoma

Scott C. Bresler,Tyler D. Menge,Trilokraj Tejasvi,Shannon A. Carty,Alexandra C. Hristov

DOI: https://doi.org/10.1111/cup.14371

2022-11-30

Journal of Cutaneous Pathology

Abstract:COVID‐19 infection and vaccination may be associated with a wide variety of cutaneous and immune manifestations. Here, we describe two patients who presented with monoclonal cutaneous T‐cell infiltrates that showed cytologic and immunophenotypic features concerning for lymphoma shortly following COVID‐19 vaccination. In one case, the eruption completely resolved. The second patient showed initial resolution, but her disease recurred and progressed following a breakthrough SARS‐CoV‐2 infection. These cases suggest that immune stimulation following exposure to SARS‐Cov‐2 protein(s) in vaccine or infection may facilitate the development of a lymphoma or lymphoproliferative disorder in susceptible individuals. Moreover, they demonstrate that separating these cases from pseudolymphomatous reactive conditions is often challenging and requires close clinical correlation.

dermatology,pathology
Systemic lupus erythematosus following COVID-19 vaccination. A systematic review of case reports and case series

Nelson Luis Cahuapaza-Gutierrez

DOI: https://doi.org/10.1177/09612033241232054

IF: 2.858

2024-02-07

Lupus

Abstract:Lupus, Ahead of Print. ObjectiveVaccination against SARS-CoV-2 reduced morbidity and mortality rates due to COVID-19 worldwide. However, several adverse effects have been documented and of great interest such as Systemic Lupus Erythematosus (SLE). The aim of the present study was to perform a systematic review of case reports and case series describing the development of SLE following COVID-19 against vaccination.MethodsCase report and case series studies were included. Systematic reviews, narratives, letters to the editor, correspondence, etc. were excluded. A selective bibliographic search was performed in the PubMed, Scopus, and EMBASE databases. In addition, the Web of Science platform was consulted. The Joanna Brigs Institute (JBI) tool was used to assess the risk of bias and quality of the studies. The Statistical Package for the Social Sciences (SPSS) 23.0 was used for the formal analysis of the descriptive data.Results12 studies met the eligibility criteria and reported a total of 16 patients. The mean age was 42.4 ± 18.69 years. A slight predominance of post-vaccination SLE was observed in females (females (n = 9) and males (n = 7). A higher association was found with Pfizer-BioNTech-162b2 vaccine (75%), followed by Sinopharm (12.5%), Moderna (6.25%). and AstraZeneca (6.25%) vaccines. Most cases were associated with the first dose (56.25%), followed by the second dose (37.5%) and only one case associated with the third dose. The number of days elapsed from vaccine administration to the appearance of the first clinical manifestations was between 1 and 30 days. Mainly there was involvement of the musculoskeletal and cutaneous system. All patients responded well to treatment with good evolution and there was no case of death.ConclusionCases of SLE associated with COVID-19 vaccination against are infrequent. However, clinical monitoring is recommended for persons receiving the SARS-CoV-2 vaccine, mainly those receiving the first dose and the Pfizer-BioNTech-162b2 vaccine.

rheumatology
Structure-based optimization of FDA-approved drug methylene blue as a c-myc G-quadruplex DNA stabilizer.

D. Chan,Hui Yang,M. Kwan,Zhen Cheng,Paul Lee,Li-Ping Bai,Zhihong Jiang,Chun‐Yuen Wong,W. Fong,C. Leung,Dik‐Lung Ma

DOI: https://doi.org/10.1016/j.biochi.2011.02.013

IF: 4.372

2011-06-01

Biochimie

Abstract:
Electron-electron interactions and spontaneous spin polarization in quantum Hall edge states.

Dempsey,Gelfand,Halperin

DOI: https://doi.org/10.1103/PHYSREVLETT.70.3639

IF: 8.6

1993-06-07

Physical Review Letters

Abstract:We study the effects of electron-electron interactions on the ground state of integral quantum Hall edge states in the Hartree-Fock approximation. We find that, in the absence of Zeeman splitting, the outermost edge state undergoes a spontaneous transition between spin-unpolarized and spin-polarized ground states at a sample-dependent critical value of the bulk filling ${\ensuremath{\nu}}_{\mathrm{bulk}}^{\mathit{c}}$\ensuremath{\sim}4. The abrupt appearance, in the spin-polarized state, of a sizable (about a magnetic length) separation between edge states of opposite spin should make the transition accessible to a range of magnetotransport experiments.
Pityriasis Rosea-like eruptions following COVID-19 mRNA-1273 vaccination: A case report and literature review

Chii-Shyan Wang,Hsuan-Hsiang Chen,Shih-Hao Liu

DOI: https://doi.org/10.1016/j.jfma.2021.12.028

IF: 3.871

2022-05-01

Journal of the Formosan Medical Association

Abstract:Pityriasis rosea (PR) is a self-limited disease with exanthematous papulosquamous rashes mostly associated with reactivation of human herpesvirus (HHV)-6 or HHV-7. PR-like eruptions, which occur along with peripheral eosinophilia, interface dermatitis, and eosinophils on histopathology, may result from medications or vaccinations. Previously, PR-like eruptions had been noted following vaccination for influenza or other vaccines. During this pandemic, acute COVID-19 infection has been related to PR or PR-like eruptions in several cases. Various COVID-19 vaccines associated with PR-like eruptions were rarely reported. Herein, we report a case of cutaneous PR-like eruptions following COVID-19 mRNA-1273 vaccination.

medicine, general & internal

LXXXVI . POLYSACCHARIDES SYNTHESISED BY MICRO-ORGANISMS III . THE MOLECULAR STRUCTURE OF GALACTO-CAROLOSE PRODUCED FROM GLUCOSE BY PENICILLIUM CHARLESII

Lichen planus flare following COVID‐19 vaccination: A case report

COVID-19-Vaccination-Induced Localized Lichen Planus Successfully Treated With Phototherapy

Chronic oral diseases secondary to COVID-19 infection or vaccination: clinical cases and a narrative review

Oral lesions after COVID-19 vaccination: Immune mechanisms and clinical approach

Onset of leukocytoclastic vasculitis following covid-19 vaccination: case based comprehensive review

Clinicopathological characteristics of cutaneous complications following COVID-19 vaccination: A case series

Viral Reactivation Following COVID-19 Vaccination: a review of the current literature

Cutaneous findings following COVID‐19 vaccination: review of world literature and own experience

COVID vaccine–induced lupus nephritis: Case report and review of the literature

Primary Cutaneous CD4 Small/Medium T-Cell Lymphoproliferative Disorder Following COVID-19 Vaccination—What Do We Know about Lymphoproliferative Disorders and Cutaneous Lymphomas after COVID-19 Vaccination? A Report of an Atypical Case and a Review of the Literature

[Features of colorectal cancer with fecal-occult-blood tests--comparison with colorectal cancer with no screening].

COVID-19 and COVID-19 Vaccine-Related Skin Ulcerations in the Lower Extremities: A Case Report and Literature Review

A peculiar post-vaccination eruption

Lipschütz ulcer following first dose of COVID‐19 tozinameran vaccine: Report of a case and review of a World Health Organization pharmacovigilance database

Rare COVID-19 vaccine side effects got lost in the shuffle. Primary cutaneous lymphomas following COVID-19 vaccination: a systematic review

Two cases of challenging cutaneous lymphoid infiltrates presenting in the context of COVID‐19 vaccination: a reactive lymphomatoid papulosis‐like eruption and a bona fide lymphoma

Systemic lupus erythematosus following COVID-19 vaccination. A systematic review of case reports and case series

Structure-based optimization of FDA-approved drug methylene blue as a c-myc G-quadruplex DNA stabilizer.

Electron-electron interactions and spontaneous spin polarization in quantum Hall edge states.

Pityriasis Rosea-like eruptions following COVID-19 mRNA-1273 vaccination: A case report and literature review